NCT03518996 is a NA clinical trial of rTMS/iTBS/tACS in Mental Disorders, sponsored by Gen Shinozaki.

Who is sponsoring NCT03518996?

NCT03518996 is sponsored by Gen Shinozaki.

What drugs are being tested in NCT03518996?

Interventions in NCT03518996: rTMS/iTBS/tACS, Sham TMS/tACS.

What condition does NCT03518996 study?

NCT03518996 studies Mental Disorders, Delirium.

Is NCT03518996 still recruiting?

NCT03518996 is currently withdrawn. Last updated 28 July 2021.

Last reviewed 2021-07-28 · How we verify

NCT03518996

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-Invasive Brain Stimulation and Delirium

Withdrawn NA Last updated 28 July 2021

What this trial tests

NA trial testing rTMS/iTBS/tACS in Mental Disorders. Withdrawn.

Timeline

1 September 2018

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	Gen Shinozaki
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Start date	1 September 2018
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across United States

Drugs / interventions tested

rTMS/iTBS/tACS
Sham TMS/tACS

Conditions studied

Mental Disorders — all drugs for Mental Disorders →
Delirium — all drugs for Delirium →

Sponsor

Gen Shinozaki

Who can join

Adults 18 to 90, any sex, with Mental Disorders or Delirium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to examine whether non-invasive brain stimulation can be used to improve cognitive deficits in patients with delirium.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transcranial alternating current stimulation for neuropsychiatric disorders: a systematic review of treatment parameters and outcomes.
Gholamali Nezhad F, Martin J, Tassone VK, Swiderski A, et al · · 2024 · cited 7× · PMID 39211537 · DOI 10.3389/fpsyt.2024.1419243

Verify or expand the search:

Other recruiting trials for Mental Disorders

Currently open trials in the same condition.

NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT06810076 — Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care · NA · active not recruiting
NCT06387290 — Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits · Phase 3 · recruiting
NCT06673966 — Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia · recruiting
NCT06930547 — Effectiveness of Smoking Cessation Education · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03518996 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gen Shinozaki
Last refreshed: 28 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03518996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing